<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03616678</url>
  </required_header>
  <id_info>
    <org_study_id>VenTouch CT007</org_study_id>
    <nct_id>NCT03616678</nct_id>
  </id_info>
  <brief_title>VenTouch OUS Feasibility Study</brief_title>
  <official_title>Evaluation of The Minimally Invasive VenTouch™ System in The Treatment of Functional Mitral Valve Regurgitation (FMR): OUS Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mardil Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mardil Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center, single-arm study to evaluate safety and efficacy of the
      VenTouch System for treatment of subjects with functional MR.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, single-arm study to evaluate safety and efficacy of the
      VenTouch System for treatment of subjects with functional MR enrolling up to 15 subjects who
      have been diagnosed with Grade 3-4 functional mitral valve regurgitation and deemed eligible
      per assessment by the inclusion/exclusion criteria. The duration of the study follow-up is 36
      months from the time of therapy adjustment. Data from this trial may be utilized in support
      of a CE study in Europe and/or a pilot IDE study in the U.S. Follow-up testing will be
      performed at 1, 3, 6, 12, 24, and 36 months post-therapy adjustment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate procedural feasibility through successful completion of implant and therapy adjustment procedures</measure>
    <time_frame>Intra-operative</time_frame>
    <description>Evaluate procedural feasibility through successful completion of implant and therapy adjustment procedures and intraoperative transesophageal echocardiographic (TEE) evidence of MR severity reduction (a minimum of one grade)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate SAE Rates</measure>
    <time_frame>1 Month</time_frame>
    <description>Evaluate Serious Adverse Event (SAE) rates at 1 month post-therapy adjustment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate SAE Rates</measure>
    <time_frame>36 Months</time_frame>
    <description>Evaluate Serious Adverse Event (SAE) rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate MR Severity</measure>
    <time_frame>36 Months</time_frame>
    <description>Evaluate MR severity reduction and mitral valve dimension reduction via echocardiographic core lab assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Reverse Ventricular Remodeling</measure>
    <time_frame>36 Months</time_frame>
    <description>Evaluate reverse ventricular remodeling via echocardiographic core lab assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Changes in Patient Symptoms by NYHA</measure>
    <time_frame>36 Months</time_frame>
    <description>Evaluate changes in patient symptoms as assessed by the NYHA functional class</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Changes in Patient Functional Status by Six-Minute Walk</measure>
    <time_frame>36 Months</time_frame>
    <description>Evaluate changes in patient functional status as assessed by Six-Minute Walk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Changes in Patient Functional Status by KCCQ</measure>
    <time_frame>36 Months</time_frame>
    <description>Evaluate changes in patient functional status as assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Functional Mitral Regurgitation</condition>
  <arm_group>
    <arm_group_label>VenTouch System Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The VenTouch System is intended for use in the treatment of functional MR (FMR) in adults who are symptomatic despite optimal medical management. It is indicated for subjects with FMR with essentially normal leaflet anatomy and motion, with mitral valve regurgitation attributable to annular and/or ventricular dilation. It is not intended to treat structural defects/degeneration of the mitral valve. The VenTouch System is intended to provide ventricular support that will encourage beneficial remodeling of the heart and, with adjustable inflatable chambers, it is intended to reduce annular dilation, correct papillary muscle displacement, and restore mitral valve leaflet coaptation, allowing proper closure of the valve, and reducing or eliminating MR. The VenTouch System is indicated for patients who have &quot;moderately severe&quot; or &quot;severe&quot; mitral regurgitation (grade 3 or 4 MR).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VenTouch System</intervention_name>
    <description>The VenTouch™ System consists of a delivery tool with a pre-loaded implant (VenTouch device) and accessories, which include a sizing tool, PEMS, chamber positioning tool, and accessories kit with luer fitting, tubing clamp, and titanium plug. The VenTouch device is offered in 6 sizes, with 4 different sized inflatable chambers available. Please refer to the VenTouch Instructions for Use for and system details.
The VenTouch device consists of three (3) inflatable silicone chambers attached to the wall of a knitted polyester support. The VenTouch device is implanted around the base of the heart and positioned at the level of the atrio-ventricular (AV) groove and the adjacent ventricular muscle. The VenTouch device is composed of biocompatible, medical-grade silicone and polyester.</description>
    <arm_group_label>VenTouch System Implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults ≥18 years of age

          2. Symptomatic FMR of grade moderately severe to severe (3 to 4) due to either ischemic
             or non-ischemic dilated cardiomyopathy with structurally normal leaflets determined by
             echocardiography (preferably with echocardiographic evidence of EROA ≥ 0.20 cm2)

          3. NYHA Class II to IV

          4. Left Ventricular Ejection Fraction (LVEF) 20%-50% determined by echocardiography

          5. Treatment and compliance with optimal guideline-directed medical therapy for heart
             failure for at least 30 days

          6. Subjects with a Class I indication for CRT implant according to current guidelines
             should have CRT implant prior to entry into the study. Subjects who have existing CRT
             implants may be included in the study if the implant has been in place for at least 90
             days; reprogramming of an implanted CRT that results in increased biventricular pacing
             (from &lt;92% to ≥92%) must be in place for at least 30 days.

          7. Left Ventricular End Diastolic Diameter (LVEDD) of 55 to 80 mm as determined by
             echocardiography

          8. Indexed Left Ventricular End Diastolic Diameter (LVEDDi) of 30 to 40 mm/m2 (where
             LVEDDi is calculated by LVEDD/Body Surface Area (BSA))

          9. Subject is willing and available to return for study follow-up

         10. Subject or legal representative understands and provides signed informed consent for
             participation in study

         11. Acceptance of subject for trial enrollment after review of all subject baseline data
             by Study Selection Committee

        Exclusion Criteria:

          1. Life expectancy of less than 12 months due to conditions other than cardiac status

          2. Anticipated need for LVAD or transplant within 12 months

          3. Chronic Obstructive Pulmonary Disease (COPD) requiring continuous home oxygen therapy
             or chronic outpatient oral steroid use

          4. American College of Cardiology / American Heart Association (ACC/AHA) Stage D heart
             failure

          5. Six-minute walk distance &lt; 150 meters

          6. Identified need for any cardiovascular surgery

          7. STS score that suggests prohibitive surgical risk as determined by Subject Selection
             Committee

          8. Untreated clinically significant coronary artery disease

          9. Any procedure, condition or cardiac anatomy that may impact or compromise the
             pericardial space (e.g. prior mitral valve surgery, CABG, epicardial pacing leads,
             pericarditis, or other procedure involving pericardial access)

         10. Percutaneous coronary intervention, acute coronary syndrome (e.g. STEMI or non-STEMI
             myocardial infarction, unstable angina) or clinically significant cardiac events (e.g.
             hypotension, syncope, arrhythmias, embolism, heart failure exacerbation or any
             hospitalization) within 30 days of enrollment

         11. Thoracic or cardiac surgery contraindication (e.g., acute respiratory distress,
             endocarditis, myocarditis, pericarditis)

         12. Significant structural abnormality of the mitral valve (e.g. flail leaflets, ruptured
             or elongated chordae, prolapsed valve, perforated valve leaflets, significant
             calcification in the annulus, or calcification in the leaflets that restricts motion)

         13. Severe symptomatic carotid stenosis

         14. Severe or sustained pulmonary hypertension, defined by resting pulmonary artery
             systolic (PAS) pressure ≥70 mmHg determined by echocardiography or right heart
             catheterization

         15. Physical evidence of right-sided congestive heart failure with echocardiographic
             evidence of moderate or severe right ventricular dysfunction or moderate to severe TR

         16. Hypotension (systolic pressure &lt;90 mmHg)

         17. Hemodynamic instability requiring inotropic support or mechanical heart assistance
             within 30 days

         18. Hypertrophic cardiomyopathy, restrictive cardiomyopathy, or any other structural heart
             disease causing heart failure other than dilated cardiomyopathy

         19. UNOS status 1 heart transplantation

         20. Creatinine &gt; 2.5 mg/dL (221 µmol/L) and/or renal failure requiring dialysis

         21. Stroke (cerebrovascular accident) or transient ischemic event (TIA) within 30 days of
             enrollment

         22. Active systemic infection or bleeding

         23. Autoimmune disorders and/or the use of immune suppression therapy

         24. Females who are pregnant (as documented by HCG beta pregnancy test in females of
             child-bearing age) or lactating

         25. Currently enrolled in another investigational drug or device study

        Intra-Operative Exclusion Criteria:

          1. Significant structural abnormality of the mitral valve (e.g. flail leaflets, ruptured
             or elongated chordae, prolapsed valve, perforated valve leaflets, significant
             calcification in the annulus, or calcification in the leaflets that restricts motion)

          2. Signs/indications of ischemia

          3. Intra-operative coronary angiography demonstrates that there is compression of the
             coronary arteries or reduction in coronary blood flow due to the VenTouch implant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sarah Hase, BS</last_name>
    <phone>763-710-4518</phone>
    <email>shase@mardil.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Libin Cardiovascular Institute, University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>William Kent, MD</last_name>
      <phone>403-944-5480</phone>
      <email>william.kent@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>William Kent, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of British Columbia, St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherin Mok</last_name>
      <phone>604-806-8383</phone>
      <email>CMok@providencehealth.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Anson Cheung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre, University Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephanie Fox, BA, RRT</last_name>
      <phone>519-685-8500</phone>
      <phone_ext>35031</phone_ext>
      <email>Stephanie.Fox@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Dave Nagpal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>4NU-470</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shakira Christie</last_name>
      <email>Shakira.Christie@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Vivek Rao, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manon Vervais</last_name>
      <phone>514-376-3330</phone>
      <phone_ext>3783</phone_ext>
      <email>manon.vervais@icm-mhi.org</email>
    </contact>
    <investigator>
      <last_name>Anita Asgar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis Bouchard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie et de Pneumologie De Québec (IUCPQ)</name>
      <address>
        <city>Québec City</city>
        <state>Quebec</state>
        <zip>G1V4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hugo Tremblay</last_name>
      <phone>418-656-8711</phone>
      <phone_ext>3797</phone_ext>
      <email>hugo.tremblay@criucpq.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>François Dagenais, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bordeaux Heart University Hospital</name>
      <address>
        <city>Bordeaux</city>
        <state>Pessac</state>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>CardioVasculäres Centrum</name>
      <address>
        <city>Frankfurt</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Semmelweis University Heart and Vascular Center</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Orsolya Kemenes</last_name>
      <phone>+36 20 8250511</phone>
      <email>studycenter.sekk@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Béla Merkely, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Pacifica Salud Hospital Punta Pacifica</name>
      <address>
        <city>Panama City</city>
        <zip>0801</zip>
        <country>Panama</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Margelis Muñoz</last_name>
      <phone>(507) 6499-9304</phone>
      <email>margelismunoz@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Christian Marin y Kall</last_name>
      <phone>305-799-1435</phone>
      <email>marinykallch@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Manuel Ochoa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centralny Szpital Kliniczny MSWiA w Warszawia</name>
      <address>
        <city>Warsaw</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Barratt</last_name>
      <phone>(+48) 662-586-856</phone>
      <email>p.barratt@vicr-group.com</email>
    </contact>
    <investigator>
      <last_name>Piotr Suwalski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>Panama</country>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>http://www.mardil.com</url>
    <description>Study Sponsor Website</description>
  </link>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 24, 2018</study_first_submitted>
  <study_first_submitted_qc>July 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2018</study_first_posted>
  <last_update_submitted>August 14, 2019</last_update_submitted>
  <last_update_submitted_qc>August 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

